ATTR amyloidosis represents transthyretin deposits resulting in various disease phenotypes. Wildtype transthyretin can result in amyloidosis in certain individuals primarily with cardiac phenotype / variant transthyretin, depending on genotype, can cause different phenotypes of amyloidotic disease. ATTR amyloidosis was originally described as familial amyloid polyneuropathy in Portugal in the 1950´s, whereas wild-type ATTR amyloidosis was first reported in the 1980s. Without disease-modifying therapy the disease results in death within a few years.
The 1st European Meeting for ATTR amyloidosis for doctors and patients took place in 2017 in Paris, with more than 500 participants, demonstrating the importance of bringing patients and doctors together. We still have limited access in different European countries to receive potent treatment, but also diagnosis remains a challenge. Therefore, we aim to strengthen this relationship between doctors and patients from different European countries with the aim of improving diagnosis, treatment and care of this devastating disease.
We hope the 2nd event of this European Meeting of doctors and patients in Berlin will be as successful as the Paris meeting. Thus we invite you to take the opportunity to join this meeting. The Langenbeck-Virchow House in Berlin has a famous medical tradition and is in the Center of the Charité Campus in downtown Berlin and provides best connections to bus, train and airport. We are looking forward to see you in Berlin.